MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $5.07 Million Stock Position in Natera, Inc. (NASDAQ:NTRA)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lessened its holdings in Natera, Inc. (NASDAQ:NTRA - Free Report) by 21.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 32,008 shares of the medical research company's stock after selling 8,550 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.'s holdings in Natera were worth $5,068,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the business. Principal Securities Inc. lifted its position in shares of Natera by 20.7% in the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock worth $54,000 after buying an additional 59 shares during the last quarter. Gladstone Institutional Advisory LLC raised its stake in shares of Natera by 1.7% in the 4th quarter. Gladstone Institutional Advisory LLC now owns 3,629 shares of the medical research company's stock valued at $574,000 after acquiring an additional 61 shares in the last quarter. Silver Oak Securities Incorporated lifted its holdings in Natera by 3.1% in the 4th quarter. Silver Oak Securities Incorporated now owns 2,963 shares of the medical research company's stock worth $470,000 after purchasing an additional 89 shares during the last quarter. Colonial Trust Co SC lifted its holdings in Natera by 7.8% in the 4th quarter. Colonial Trust Co SC now owns 1,325 shares of the medical research company's stock worth $210,000 after purchasing an additional 96 shares during the last quarter. Finally, Blue Trust Inc. boosted its position in Natera by 104.3% during the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock worth $30,000 after purchasing an additional 97 shares during the period. 99.90% of the stock is currently owned by institutional investors.

Insider Transactions at Natera

In related news, CFO Michael Burkes Brophy sold 2,562 shares of Natera stock in a transaction dated Monday, March 31st. The shares were sold at an average price of $138.41, for a total transaction of $354,606.42. Following the completion of the transaction, the chief financial officer now directly owns 75,557 shares of the company's stock, valued at $10,457,844.37. This trade represents a 3.28% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Steven Leonard Chapman sold 87,272 shares of the business's stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $143.40, for a total transaction of $12,514,804.80. Following the completion of the transaction, the chief executive officer now owns 203,354 shares in the company, valued at approximately $29,160,963.60. This trade represents a 30.03% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 152,436 shares of company stock valued at $22,019,079. Corporate insiders own 7.60% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on NTRA. Royal Bank of Canada started coverage on shares of Natera in a research report on Thursday, March 13th. They issued an "outperform" rating and a $251.00 price target on the stock. UBS Group lifted their target price on shares of Natera from $211.00 to $218.00 and gave the stock a "buy" rating in a report on Friday, May 9th. Canaccord Genuity Group reissued a "buy" rating and set a $180.00 target price on shares of Natera in a research report on Wednesday, February 26th. Morgan Stanley raised their price target on Natera from $176.00 to $185.00 and gave the company an "overweight" rating in a research report on Wednesday, March 5th. Finally, The Goldman Sachs Group boosted their price objective on Natera from $160.00 to $190.00 and gave the stock a "buy" rating in a research report on Tuesday, January 28th. One analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Natera has a consensus rating of "Moderate Buy" and a consensus price target of $182.12.

Natera Stock Up 2.1%

NTRA opened at $152.59 on Monday. Natera, Inc. has a fifty-two week low of $92.14 and a fifty-two week high of $183.00. The company has a market capitalization of $20.84 billion, a P/E ratio of -86.70 and a beta of 1.79. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. The firm's fifty day moving average price is $148.71 and its two-hundred day moving average price is $156.96.

Natera (NASDAQ:NTRA - Get Free Report) last posted its earnings results on Thursday, May 8th. The medical research company reported ($0.50) earnings per share for the quarter, beating analysts' consensus estimates of ($0.59) by $0.09. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The business had revenue of $501.83 million for the quarter, compared to analysts' expectations of $446.68 million. During the same quarter in the previous year, the firm posted ($0.56) earnings per share. The firm's revenue for the quarter was up 36.5% on a year-over-year basis. On average, analysts anticipate that Natera, Inc. will post -1.49 EPS for the current year.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.